# A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke

> **NCT06755944** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Shijiazhuang Yiling Pharmaceutical Co. Ltd** · enrollment: 360 (estimated)

## Conditions studied

- Stroke, Ischemic

## Interventions

- **DRUG:** XY03-EA

## Key facts

- **NCT ID:** NCT06755944
- **Lead sponsor:** Shijiazhuang Yiling Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-12-15
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06755944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06755944, "A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06755944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*